Omeros Corporation.
company in Seattle, United States
- Reports this week
- 1
- Active events
- 1
- Connections
- 29
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.Some support4 reports1 development inside
-
Omeros Corporation analysts expect the company to reach breakeven soon, while Trump pledged to unleash American oil and gas.Speculative1 report
-
BlackRock became the largest shareholder in Omeros Corporation on August 12, 2025, while Gregory Demopulos was appointed CEO.Some support1 report
-
Omeros Corporation is based in Seattle.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Omeros Corporation this week
News at the entities that move Omeros Corporation most-
FDA StructuralThe FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.Moves Omeros Corporation
-
European Medicines Agency StructuralGlenn attended a congress in Amsterdam and participated in a panel with an official from the European Medicines Agency.Moves Omeros Corporation
-
SEC StructuralIntuit filed a Form 4 with the SEC regarding insider share sales on August 30, 2026.Moves Omeros Corporation
-
Seattle Shared contextIn Seattle and West Seattle, a parks project is expanding local green space while a utility completes an EV charging project.Moves Omeros Corporation
-
Los Angeles Shared contextSharon Osbourne is attempting to sell her home in the Greater Los Angeles area.Moves Omeros Corporation
-
Chicago Shared contextActivism seeks to close a Broadview Ice Detention Center while DHS uses GPS ankle monitors on immigrants in the Chicago area.Moves Omeros Corporation
Connections
The 10 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
Omeros Corporation's drug candidates require formal regulatory review and approval from the FDA.
-
European Medicines Agency Structural
EMA formally reviewed Omeros's marketing authorization application and issued a negative opinion.
-
SEC Structural
Omeros Corporation is subject to the regulatory oversight and disclosure requirements of the SEC.
-
National Institute on Drug Abuse Structural
NIDA provides financial funding to Omeros Corporation for the development of its drug candidate OMS527.
-
Seattle Shared context
Omeros Corporation is consistently reported as being based in Seattle.
-
Chicago Shared context
The relationship is inferred from a single snapshot noting a third entity operates in Chicago.
-
Los Angeles Shared context
Omeros Corporation is located within the geographical context of Los Angeles.
-
Paris Mentioned together
No evidence found linking Paris and Omeros Corporation.
History
Events by the month they beganSeptember 2026
2 eventsJune 2026
5 events- Omeros Corporation's drug received FDA approval and is currently undergoing review by the European Medicines Agency.
- Omeros Corporation, based in Seattle, has submitted a Biologics License Application (BLA) to the FDA seeking approval for its drug candidate, narsoplimab.
- Omeros Corporation analysts expect the company to reach breakeven soon, while Trump pledged to unleash American oil and gas.
- BlackRock became the largest shareholder in Omeros Corporation on August 12, 2025, while Gregory Demopulos was appointed CEO.
- Omeros Corporation is based in Seattle.